高级搜索

原发性肝癌分子靶向药物临床研究进展

Clinical Advances of Molecular-targeted Therapy on Primary Hepatocellular Carcinoma

  • 摘要: 原发性肝癌是世界范围内主要死亡原因之一。尽管各种肝癌治疗方法,如根治性外科切除、肝脏移植、局部消融治疗、动脉化疗栓塞、放疗、系统性化疗等近年来发展迅速,但仍存在临床疗效欠佳、5年生存率低的问题。近10年来,随着对肝癌基础研究的深入,肝癌发生发展信号转导通路的明确,以索拉非尼(Sorafenib)为代表的分子靶向药物在进展期肝癌治疗中日益受到重视并广泛应用,延长了进展期肝癌的生存时间,改善了患者的生存质量。本文就肝癌分子靶向治疗的研究进展及应用现状作一综述。

     

    Abstract: Primary hepatocellular carcinoma is one of major causes of death worldwide. Although advanced treatment methods have been developed recently,such as surgical resection,liver transplantation,local ablation,transcatheter arterial chemoembolization,radiotherapy,systemic chemotherapy,etc.,it is still showed very low clinical efficacies with very low 5-years survival rate. Over the past 10 years,as the investigation advances in basic research of hepatocellular carcinoma,as well as the development of signal transduction pathway of hepatocellular carcinoma becomes more clear,the molecular targeted drugs for hepatocellular carcinoma,represented by Sorafenib,are increasingly valued in clinic and used in the treatment of advanced hepatocellular carcinoma widely. In addition,the survival time of patients with advanced hepatocellular carcinoma has been prolonged and the qualities of life have been improved. In this article,the progress and applications of molecular targeted therapy of hepatocellular carcinoma have been reviewed.

     

/

返回文章
返回